摘要
The spread of tuberculosis (TB), especially multidrug-resistant TB and extensively drug -resistant TB, has strongly motivated the research and development of new anti -TB drugs. New strategies to facilitate drug combinations, including pharmacokinetics-guided dose optimization and toxicology studies of first- and second -line anti -TB drugs have also been introduced and recommended. Liquid chromatography -mass spectrometry (LC -MS) has arguably become the gold standard in the analysis of both endo- and exo-genous compounds. This technique has been applied successfully not only for therapeutic drug monitoring (TDM) but also for pharmacometabolomics analysis. TDM improves the effectiveness of treatment, reduces adverse drug reactions, and the likelihood of drug resistance development in TB patients by determining dosage regimens that produce concentrations within the therapeutic target Based on TDM, the dose would be optimized individually to achieve favorable outcomes. Pharmacometabolomics is essential in generating and validating hypotheses regarding the metabolism of anti -TB drugs, aiding in the discovery of potential biomarkers for TB diagnostics, treatment monitoring, and outcome evaluation. This article highlighted the current progresses in TDM of anti -TB drugs based on LC -MS bioassay in the last two decades. Besides, we discussed the advantages and disadvantages of this technique in practical use. The pressing need for non-invasive sampling approaches and stability studies of anti -TB drugs was highlighted. Lastly, we provided perspectives on the prospects of combining LC -MS -based TDM and pharmacometabolomics with other advanced strategies (pharmacometrics, drug and vaccine developments, machine learning/artificial intelligence, among others) to encapsulate in an all-inclusive approach to improve treatment outcomes of TB patients. (c) 2023 The Author(s). Published by Elsevier B.V. on behalf of Xi'an Jiaotong University. This is an open access article under the CC BY -NC -ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
学科与关键词
- A Review of Clinical Pharmacokinetic and Pharmacodynamic Relationships and Clinical Implications for Drugs Used to Treat Multi-drug Resistant TuberculosisWilby, Kyle John*; Hussain, Farhat NazEUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2020, 45(3): 305-313.被引 5
- Quantitative assessment of the activity of antituberculosis drugs and regimensChirehwa, Maxwell T.*; Velasquez, Gustavo E.; Gumbo, Tawanda; McIlleron, HelenExpert Review of Anti-Infective Therapy, 2019, 17(6): 449-457.被引 3
- The novel potential biomarkers for multidrug-resistance tuberculosis using UPLC-Q-TOF-MSHuang, Huai; Han, Yu-Shuai; Chen, Jing; Shi, Li-Ying; Wei, Li-Liang; Jiang, Ting-Ting; Yi, Wen-Jing; Yu, Yi; Li, Zhi-Bin; Li, Ji-Cheng*Experimental Biology and Medicine, 2020, 245(6): 501-511.被引 10
